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We investigated the presence of  Candida dubliniensis among isolates previously identified as Candida albicans
and maintained in a yeast stock collection from 1994 to 2000. All isolates were serotyped and further evaluated for
antifungal susceptibility profile. After doing a screening test for C. dubliniensis isolates based on the capability of
colonies to grow at 42°C, its final identification was obtained by randomly amplified polymorphic DNA (RAPD)
analysis using three different primers. A total of 46 out of 548 screened isolates did not exhibit growth at 42°C and
were further genotyped by RAPD. Eleven isolates were identified as C. dubliniensis with RAPD analysis.  Regarding
serotypes, 81.5% of  C. albicans and all C. dubliniensis isolates belonged to serotype A. Of note, 9 out of 11 C.
dubliniensis isolates were obtained from patients with acquired immunodeficiency syndrome (Aids) and all of them
were susceptible to azoles and amphotericin B.  We found 17 (3%) C. albicans isolates that were dose-dependent
susceptibility or resistant to azoles.  In conclusion, we found a low rate of  C. dubliniensis isolates among stock
cultures of yeasts previously identified as C. albicans. Most of these isolates were recovered from oral samples of Aids
patients and exhibited high susceptibility to amphotericin B and azoles. C. albicans serotype A susceptible to all
antifungal drugs is the major phenotype found in our stock culture.
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Recently, Sullivan et al. (1995) described the novel
species Candida dubliniensis, primarily associated with
oral candidosis in human immunodeficiency virus (HIV)
infected and acquired immunodeficiency syndrome (Aids)
patients. C. dubliniensis shares many phenotypic char-
acteristics with Candida albicans isolates and molecular
methods are needed to distinguish both species (Sullivan
et al. 1995, Coleman et al. 1997, Kirkpatrick et al. 1998,
Sullivan & Coleman 1998). Probably, this new species has
been present in the community for a long period of time
and has been misidentified as C. albicans (Schorling et
al. 2000). Definitive identification of C. dubliniensis is a
problem in routine diagnostic laboratories and surveil-
lance studies performed by reference laboratories are nec-
essary to better understand the epidemiology of this new
species.
There are currently a wide variety of molecular tech-
niques capable of identifying C. dubliniensis, including:
DNA fingerprinting techniques using restriction endo-
nuclease (REA) analysis, pulsed field gel electrophore-
sis-based methods, DNA fingerprinting using specific
probes and polymerase chain reaction (PCR) based meth-
ods. Unfortunately, these methods are labor-intensive, ex-
pensive, and not readily applicable to routine use for iden-
tification purposes in most clinical microbiology diagnos-
tic laboratories (Mannarelli & Kurtzman 1998, Kurzai et al.
1999, Sullivan et al. 1999, Park et al. 2000).
In Brazil and South America there are a small number
of reports addressing the epidemiology of this emergent
species. The aims of this study were to identify C.
dubliniensis strains among isolates from a large yeast
culture collection including strains that were previously
identified as C. albicans and to evaluate the serotypes
and susceptibility profiles of isolates of both species.
MATERIALS AND METHODS
Samples - The isolates tested were selected among
strains previously identified as C. albicans and maintained
at the yeast stock collection of the Special Mycology
Laboratory, Universidade Federal de São Paulo, between
1994 and 2000. The samples had been stored at -70°C in
10% glycerol, for different periods of time. We included
strains isolated from different body fluids of HIV positive
and negative patients as follow: blood, urine, esophageal
and oropharyngeal samples.
C. albicans identification - All isolates were inocu-
lated on CHROMagar Candida medium (CHROMagar
Microbiology, Paris, France) and incubated at 30oC for up
to 5 days with daily examination looking for light green
colonies (typical of C. albicans) and dark green colonies
(typical of C. dubliniensis). Representative light green
and/or dark green colonies were further purified by sub-
culture on Sabouraud dextrose agar (SDA, Difco Labora-
tories, Detroit, MI) and were tested for their ability to
produce chlamydoconidia on corn meal Tween 80 agar
(Kirkpatrick et al. 1998, Odds et al. 1998).
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Serotyping assay - All strains were prepared for slide
agglutination serotyping with serodiagnostic reagent
number 6 from Candida Check kit (Iatron Laboratories,
Inc., Higashi-Kanda, Chiyoda, Tokio, Japan), as suggested
in the package insert. C. albicans cultures were incubated
on Sabouraud-dextrose agar plates for 48 h at 25oC. Small
amounts of specimen yeast cells were inoculated onto a
Candida Check test tray and approximately 0.05 ml of spe-
cific serum (number 6) was added for testing and physi-
ological saline was added as control. The glass test tray
was stirred for about 1-2 min. A positive agglutination
reaction was interpreted by the visualization of aggre-
gates considered to be indicative of C. albicans serotype
A. Negative results in the agglutination reaction with re-
agent number 6 were considered to be indicative of C.
albicans serotype B (Sullivan et al. 1995).
C. dubliniensis screening test - Following isolation
on CHROMagar medium, a small portion of a single colony
of each isolate was streaked for subculture over the sur-
face on SDA agar plate and incubated at 42oC as previ-
ously described. All isolates that grew poorly or did not
grow at all when incubated at 42oC were further genotyped
by RAPD assays (Gales et al. 1998, Pinjon et al. 1998).
RAPD analysis - Template DNA for RAPD analysis
was prepared from yeast cells grown in 2 ml of YPD me-
dium for 16 h at 30oC with agitation (220 r.p.m.) or until a
density of 2 x 108 cells/ml be achieved. DNA was extracted
using a rapid, small-scale isolation protocol described
previously (Wash et al. 1994). RNA was removed by treat-
ment with RNase A (Amersham Pharmacia Biotech,
Piscataway, NJ, USA) for 1 h at 37oC. DNA concentration
and purity were determined by optical density at 260 nm
and ratio O.D. 260 nm/280 nm determinations, respectively.
RAPD tests were also performed with template DNA from
reference strains of C. albicans (ATCC 76615) and C.
dubliniensis (CBS 7987). RAPD analysis was performed
as described previously with the oligonucleotide primer
CDU (5’ GCG ATC CCC A 3’) (Sullivan et al. 1995), M2 (5’
CTT GAT TGC C 3’) and the oligonucleotide primer B-14
(5’ GAT CAA GTC C 3’), the latter previously reported by
Bauer et al. (1993). Aliquots of 40 ng of total DNA were
added to a 25 µl reaction containing 2.5 µl of a 10 x PCR
buffer (100 mM Tris-HCl, pH 8.3, 500 mM KCl, 3.5 mM
MgCl2), 4 µl of dNTP mix (1.25 mM each dNTP), 0.4 µM of
primer, 0.5% (vol/vol) Tween 20 and 1.0 unit of Taq DNA
polymerase (Amersham Pharmacia Biotech). Cycle condi-
tions were 94oC for 1 min, 40oC for 1 min, 72oC for 2 min,
for 45 cycles and a final extension at 72oC for 10 min, in a
Perkin-Elmer DNA thermocycler (Gene Amp PCR System
9600).  RAPD products were separated by electrophore-
sis for 3 h at 100 V in 1.5% (wt/vol) agarose gels using
Tris-Acetate-EDTA (TAE) buffer. Following electrophore-
sis, gels were stained with a solution containing 0.5 µg/ml
ethidium bromide for 10 min and destained twice for 15
min in 300 ml of distilled water. The gels were observed on
UV transilluminator and photographed. RAPD profiles
were defined with visual analysis, comparing the bands
derived of the reference strains and the samples testing.
Susceptibility testing - All isolates were tested for
susceptibility to amphotericin B, fluconazole, itraconazole
and ketoconazole by using a broth microdilution assay
performed in accordance with the NCCLS M27-A stan-
dard (NCCLS 1997). Reference grade powders of
fluconazole (Pfizer Inc., New York, NY, USA), itraconazole
(Janssen Pharmaceutical, Titusville, New Jersey, NY, USA),
ketoconazole (Janssen Pharmaceutical) and amphotericin
B (Sigma Chemical Corporation, Saint Louis, MO, USA)
were used to obtain final drug dilutions ranging from 0.125
to 64 µg/l, 0.007 to 4 µg/ml, 0.015 to 8 µg/ml and 0.03 to 16
µg/ml, respectively. Briefly, broth microdilution testing was
performed in sterile, flat-bottom 96-well microplates
(Costar, Corning Incorporated, New York, USA), with
RPMI-1640 (Angus Buffers & Biochemicals, Niagara Falls,
NY, USA) with L-glutamine, without bicarbonate, and buff-
ered with MOPS at pH 7.0. The microplates containing
the double of the final concentration of azoles were made
in advance and stored at -70oC for no more than three
weeks until use. On the test day, the inoculum suspen-
sion had a turbidity adjusted by the spectrophotometer
to that produced by a 0.5 McFarland standard at 530 nm
wavelength. A volume of 100 µl of the adjusted inoculum
suspension was dispensed in each well resulting in the
desired final drug concentration and inoculum size be-
tween 0.5 and 2.5 X 103 cells/ml. The plates were incu-
bated at 35oC for 48 h. Quality control strain (C.
parapsilosis ATCC 22019) was included on each day of
the assay to check the accuracy of the drug dilutions and
the reproducibility of the results.
The Minimal Inhibitory Concentration (MIC) of am-
photericin B was defined as the lowest concentration able
to inhibit any visual growth. The MIC of azoles was the
lowest concentration that exhibited prominent reduction
in the turbidity, when compared with the growth control
(drug-free) well  (NCCLS 1997).
Breakpoint definitions for fluconazole and itraconazole
MICs were those proposed by the NCCLS (1997). Due to
the lack of consensual definitions of breakpoints for
ketoconazole and amphotericin B MICs, arbitrary values
were established, following those suggested in previous
studies (Rodriguez-Tudela et al. 1995, St-Germain et al.
1995, Milan et al. 1998).
RESULTS
A total of 548 isolates previously identified as C.
albicans on the bases of phenotypic characterization were
considered for analysis. Among the 548 samples tested
on CHROMagar Candida medium, only 10 exhibited a dark
green colony color while the others exhibited a common
light green colony color. All of them produced
chlamydoconidia on corn meal Tween 80 agar. The clini-
cal sources of the isolates evaluated were: blood (100),
urine (86), esophageal (97), and oropharyngeal samples
(265). All blood and urine isolates were obtained from
HIV negative critical care patients. All esophageal samples
and 50% of the oropharyngeal isolates were obtained from
HIV positive patients.
After doing the temperature growth test, 46 isolates
grew very slowly or not at all in these conditions and
were further subjected to the RAPD analysis using three
different primers. Based on RAPD findings, we concluded
that 11 isolates exhibited the same profile of the CBS 7987
C. dubliniensis control organism. Among these 11 C.
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dubliniensis isolates found, only 2 exhibited a typical dark
green colony color on CHROMagar Candida medium.
Fig. 1 illustrates the RAPD banding patterns of the 11
clinical isolates obtained with RAPD using the 3 primers
tested. Using the primer CDU, C. dubliniensis and C.
albicans isolates yielded RAPD profiles with 7 and 6
strong bands, respectively, with molecular sizes ranging
from 300 to 1300 bp. (Fig. 1A). The RAPD assay with
primer B-14 yielded 6 strong bands to C. dubliniensis and
5 to C. albicans, with molecular sizes ranging from 400 to
2000 bp (Fig. 1B).  Finally, using the primer M-2 we got 8
strong bands with C. dubliniensis and 5 with C. abicans
isolates, with molecular sizes ranging from 300 to 1600 bp
(Fig. 1C).  The other 35 isolates produced RAPD profiles
very similar to that obtained with the C. albicans refer-
ence strain ATCC 76615.
All C. dubliniensis isolates belonged to serotype A.
C. albicans isolates serotype A responded for 81.5% of
all C. albicans strains. The distribution of C. albicans
serotypes was very similar among isolates obtained from
different clinical sources.
The 11 C. dubliniensis isolates exhibited MIC values
ranging from 0.125 to 0.5 for amphotericin B, 0.06 to 0.25
µg/ml for fluconazole, 0.015 to 0.06 µg/ml for itraconazole
and 0.015 to 0.03 µg/ml for ketoconazole. These data indi-
cated that all of the C. dubliniensis isolates were suscep-
tible to the 4 antifungal drugs tested. The range of the
MIC values obtained with C. albicans isolates was larger
than that obtained with C. dubliniensis isolates, as illus-
trated in Table I. It was possible to identify 17 C. albicans
isolates resistant and/or with susceptibility dose depen-
dent (SDD) to azoles, most of them (76%) obtained from
Aids patients. The MIC values exhibited by the azoles
SDD/resistant isolates were presented in Table II.
DISCUSSION
In the present series we found a low prevalence rate
of C. dubliniensis (2%) among 548 yeast isolates obtained
from a stock culture collection consisting of isolates that
had been previously identified as C. albicans. The evalu-
ated isolates were collected from different clinical sources
of HIV positive and negative patients.  As expected, the
11 C. dubliniensis isolates were obtained from oropha-
ryngeal samples and 9 of them were cultured from HIV
positive patients.
C. dubliniensis isolates have been mostly reported
among Aids patients. The most extensive reported data
of the incidence of C. dubliniensis in HIV infected and
Aids patients comes from Ireland with a frequency about
18-32% (Coleman et al. 1997, Sullivan et al. 1999). Studies
conducted in the United States have reported oral inci-
dence rates for C. dubliniensis in HIV infected individu-
als ranging from 11.1 to 17.5% (Kirkpatrick et al. 1998,
Meiller et al. 1999). In South America, the prevalence of C.
dubliniensis isolates seems to be lower than that exhib-
ited in north hemisphere countries. A recent prospective
and multicenter study conducted by Milan et al. (2001),
including the evaluation of 108 Brazilian Aids patients
with oropharyngeal candidiasis, found that only 3 of them
were harboring C. dubliniensis at the time they were
sampled. In accordance with the mentioned findings by
Milan et al. (2001), other authors from Latin American
medical centers have reported only limited number of Aids
patients who were colonized and/or infected by C.
dubliniensis (Sano et al. 2000, Alves et al. 2001).
The prevalence rate of C. dubliniensis found in our
yeast stock collection was similar to that reported by similar
studies performed by other investigators. Odds et al.
(1998), using molecular typing for yeast identification,
evaluated 2,589 isolates from stock cultures of yeasts origi-
nally identified as C. albicans and found that 2.1% of
Fig. 1: agarose gels showing amplified DNA products generated
using the CDU primer (A), B-14 primer (B) and the M2 primer (C),
in RAPD analysis of Candida albicans and C. dubliniensis isolates.
The profiles shown in lanes 2 and 3 correspond to the C. dubliniensis
type strain CBS 7987 and the C. albicans reference strain ATCC
76615, respectively. Profiles shown in lanes 4-14 correspond to
the C. dubliniensis isolates identified in this study, whereas profiles
shown in lane 15 correspond to C. albicans isolate. Lane 1, mo-
lecular weight size reference markers (100 bp ladder).
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them were correctly identified as C. dubliniensis. In a simi-
lar study performed by Jabra-Rizk et al. (2000) the preva-
lence of C. dubliniensis identification was 1.2% among
the 1,251 isolates previously identified as C. albicans.
In the present study we found two C. dubliniensis
isolates from oropharyngeal cultures obtained from HIV
negative health carriers. These findings are in accordance
with previous report of Coleman et al. (1997) that reported
3% of prevalence of this new species in health carriers
from Ireland.
Isolation of C. dubliniensis from clinical sources other
than oropharyngeal samples obtained from HIV negative
patients have been reported with increasing frequency.
C. dubliniensis isolates have been isolated from different
clinical sources, including blood, urine, vaginal and feces
from diabetic patients, surgical patients, and patients sub-
mitted to organ transplantation (Meis et al. 1999, Brandt
et al. 2000, Willis et al. 2000).
Several methods for screening of C. dubliniensis have
been reported, including culture on CHROMagar Candida,
evaluation of their ability to grow at 42 or 45°C, evalua-
tion of β-D-glucosidase activity as well as their carbohy-
drate assimilation pattern (Sullivan et al. 1995, 1997,
Schoofs et al. 1997, Pinjon et al. 1998, Salkin et al. 1998). Of
note, as mentioned by other investigators, most of our
cultures of C. dubliniensis that had been stocked by long
periods of time and did not exhibited the typical dark green
colony color on CHROMagar Candida medium when in-
cubated up to 5 days (Schoofs et al. 1997, Sullivan et al.
1999). In our study, the inability of the organism to grow
at high temperature (42°C) was selected as a screening
test for C. dubliniensis because it is inexpensive and easy
to perform, generates results after 48 h incubation with a
clear reading criteria and has been successfully used by
different authors (Kirkpatrick et al. 1998, Tintelnot et al.
2000).
In the present study, the final identification of C.
dubliniensis was obtained by RAPD analysis, a method
standardized in our laboratory that has been used by sev-
eral investigators as a molecular tool for the identification
of microorganisms (Sullivan et al. 1995, Coleman et al.
1997, Melo et al. 1998, Park et al. 2000, Milan et al. 2001). It
TABLE I
Antifungal susceptibility pattern of Candida albicans and Candida dubliniensis isolates determined by the NCCLS broth
microdilution method
Drug Species/serotype (n) MIC range (µg/ml) MIC50 (µg/ml) MIC90 (µg/ml)
AMB C. albicans/A (392) 0.125-1.0 0.5 0.5
C. albicans/B (91) 0.125-1.0 0.5 1.0
C. albicans - total (486) 0.125-1.0 0.5 0.5
C. dubliniensis (11) 0.125-0.5 0.25 0.5
FLZ C. albicans/A (392) 0.06-64 0.25 0.5
C. albicans/B (91) 0.125-64 0.25 0.5
C. albicans - total (486) 0.06-64 0.25 0.5
C. dubliniensis (11) 0.06-0.25 0.125 0.25
ITZ C. albicans/A (392) 0.007-4.0 0.03 0.06
C. albicans/B (91) 0.007-0.25 0.03 0.06
C. albicans - total (486) 0.007-4.0 0.03 0.06
C. dubliniensis (11) 0.015-0.06 0.03 0.06
KTZ C. albicans/A (310) 0.007-8.0 0.015 0.06
C. albicans/B (73) 0.015-2.0 0.015 0.03
C. albicans - total (386) 0.007-8.0 0.015 0.06
C. dubliniensis (11) 0.015-0.03 0.015 0.03
NCCLS: National Committee for Clinical Laboratory Standards; AMB: amphotericin B; FLZ: fluconazole; ITZ: itraconazole; KTZ:
ketoconazole; MIC: minimal inhibitory concentration; MIC50: MIC value able to inhibit 50% of the samples tested; MIC90: MIC
value able to inhibit 90% of the samples tested; n: number of the isolates
TABLE II
Candida albicans isolates exhibiting resistance or susceptible
dose-dependent to fluconazole, itraconazole and/or
ketoconazole
         MIC (mg/ml)
Code Source FLZ ITZ KTZ Serotype
A30 Oral cavities a 64 4.0 4.0 A
1564 Esophagus a 64 0.06 0.125 A
1173 Urine 64 0.015 4.0 A
447803 Urine 64 0.007 2 B
1542 Esophagus a 32 0.06 0.06 A
1446 Esophagus a 16 0.5 0.125 A
1416 Esophagus a 16 0.25 0.125 A
A13 Oral cavities a 8 0.25 0.125 B
A64 Oral cavities a 2 0.125 0.5 A
C20b Oral cavities 2 0.06 0.25 A
A16 Oral cavities a 1 0.06 1 A
A98 Oral cavities a 1 0.015 1 A
A80 Oral cavities a 0.5 0.125 0.25 A
1407 Esophagus a 0.25 4 0.015 A
112-H Blood 0.25 0.25 - A
A19 Oral cavities a 0.25 0.125 8 A
A20 Oral cavities a 0.125 0.125 0.25 A
MIC: minimal inhibitory concentration; FLZ: fluconazole; ITZ:
itraconazole; KTZ: ketoconazole; a: patient with Aids
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is noteworthy that the 3 different primers we used for
RAPD analysis exhibited several high density bands that
allowed a clear visual interpretation of the DNA finger-
printing exhibited by C. dubliniensis and C. albicans iso-
lates.
All isolates of C. dubliniensis we found belonged to
serotype A.  The literature reports that C. dubliniensis
isolates are able only to express serotype A phenotype of
C. albicans (Schoofs et al. 1997, Sullivan & Coleman 1998).
Regarding to the antifungal susceptibility profile of the
isolates, all them were susceptible to azoles and amphot-
ericin B. Pfaller et al. (1999a), after evaluating a total of 71
C. dubliniensis isolates, found that most of them are
highly susceptible to amphotericin B and azoles.
In Brazil, C. albicans serotype A susceptible to all
antifungal drugs seems to be the most prevalent pheno-
type of C. albicans isolates, regardless of the origin of
the sample. We found a frequency between 75.6% and
88.4% of serotype A among isolates obtained from HIV
negative and positive, including all different clinical
sources. This finding is in accordance with previous pub-
lications (Pires et al. 1996, Sant’Ana et al. 2002).
Despite the high susceptibility to azoles exhibited by
the 486 C. albicans isolates, we found 17 (3.5%) strains
exhibiting susceptibility dose dependent status or resis-
tance to azoles. It is noteworthy that 13 of the mentioned
less susceptible isolates were recovered from Aids pa-
tients.  C. albicans isolates resistant to fluconazole has
been mainly reported among Aids patients with history
of a long period of exposure to azoles (Persons et al. 1991,
Millon et al. 1994, Barchiesi et al. 1996).
In conclusion, the clinical sources of C. dubliniensis
in Brazil appears to be similar to that exhibited by isolates
evaluated in other series of yeast stock cultures from Eu-
rope and United States. Most of the isolates were ob-
tained from oral cavities of HIV positive and Aids pa-
tients. C. albicans serotype A susceptible to all antifun-
gal drugs was the major phenotype of C. albicans iso-
lates stocked at our yeast collection, regardless of the
clinical source of the strains.
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